Literature DB >> 23269072

Current preclinical models for the advancement of translational bladder cancer research.

David J DeGraff1, Victoria L Robinson, Jay B Shah, William D Brandt, Guru Sonpavde, Yibin Kang, Monica Liebert, Xue-Ru Wu, John A Taylor.   

Abstract

Bladder cancer is a common disease representing the fifth most diagnosed solid tumor in the United States. Despite this, advances in our understanding of the molecular etiology and treatment of bladder cancer have been relatively lacking. This is especially apparent when recent advances in other cancers, such as breast and prostate, are taken into consideration. The field of bladder cancer research is ready and poised for a series of paradigm-shifting discoveries that will greatly impact the way this disease is clinically managed. Future preclinical discoveries with translational potential will require investigators to take full advantage of recent advances in molecular and animal modeling methodologies. We present an overview of current preclinical models and their potential roles in advancing our understanding of this deadly disease and for advancing care. ©2012 AACR.

Entities:  

Mesh:

Year:  2012        PMID: 23269072     DOI: 10.1158/1535-7163.MCT-12-0508

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  16 in total

1.  ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms.

Authors:  Phillip L Palmbos; Lidong Wang; Huibin Yang; Yin Wang; Jacob Leflein; McKenzie L Ahmet; John E Wilkinson; Chandan Kumar-Sinha; Gina M Ney; Scott A Tomlins; Stephanie Daignault; Lakshmi P Kunju; Xue-Ru Wu; Yair Lotan; Monica Liebert; Mats E Ljungman; Diane M Simeone
Journal:  Cancer Res       Date:  2015-10-15       Impact factor: 12.701

2.  Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) model.

Authors:  Peter A Raven; Ninadh M D'Costa; Igor Moskalev; Zheng Tan; Sebastian Frees; Claudia Chavez-Munoz; Alan I So
Journal:  Am J Clin Exp Urol       Date:  2018-12-20

3.  p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice.

Authors:  Venkateshwar Madka; Yuting Zhang; Qian Li; Altaf Mohammed; Puneet Sindhwani; Stan Lightfoot; Xue-Re Wu; Levy Kopelovich; Chinthalapally V Rao
Journal:  Neoplasia       Date:  2013-08       Impact factor: 5.715

Review 4.  Modelling bladder cancer in mice: opportunities and challenges.

Authors:  Takashi Kobayashi; Tomasz B Owczarek; James M McKiernan; Cory Abate-Shen
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

5.  Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas.

Authors:  Feng He; Jonathan Melamed; Moon-Shong Tang; Chuanshu Huang; Xue-Ru Wu
Journal:  Cancer Res       Date:  2015-03-20       Impact factor: 12.701

6.  Increased expression of L-selectin (CD62L) in high-grade urothelial carcinoma: A potential marker for metastatic disease.

Authors:  Dharamainder Choudhary; Poornima Hegde; Olga Voznesensky; Shilpa Choudhary; Stavros Kopsiaftis; Kevin P Claffey; Carol C Pilbeam; John A Taylor
Journal:  Urol Oncol       Date:  2015-01-22       Impact factor: 3.498

7.  Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex.

Authors:  Scott J Weir; Prasad Dandawate; David Standing; Sangita Bhattacharyya; Prabhu Ramamoorthy; Parthasarathy Rangarajan; Robyn Wood; Amanda E Brinker; Benjamin L Woolbright; Mehmet Tanol; Tammy Ham; William McCulloch; Michael Dalton; Gregory A Reed; Michael J Baltezor; Roy A Jensen; John A Taylor; Shrikant Anant
Journal:  Cell Death Dis       Date:  2021-05-31       Impact factor: 8.469

Review 8.  Preclinical Models for Bladder Cancer Research.

Authors:  Shaoming Zhu; Zheng Zhu; Ai-Hong Ma; Guru P Sonpavde; Fan Cheng; Chong-Xian Pan
Journal:  Hematol Oncol Clin North Am       Date:  2021-04-16       Impact factor: 2.861

9.  Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank.

Authors:  Ashish M Kamat; Piyush Agarwal; Trinity Bivalacqua; Stephanie Chisolm; Sia Daneshmand; James H Doroshow; Jason A Efstathiou; Matthew Galsky; Gopa Iyer; Wassim Kassouf; Jay Shah; John Taylor; Stephen B Williams; Diane Zipursky Quale; Jonathan E Rosenberg
Journal:  Bladder Cancer       Date:  2016-04-27

10.  Dual ligand/receptor interactions activate urothelial defenses against uropathogenic E. coli.

Authors:  Yan Liu; Sylvie Mémet; Ricardo Saban; Xiangpeng Kong; Pavel Aprikian; Evgeni Sokurenko; Tung-Tien Sun; Xue-Ru Wu
Journal:  Sci Rep       Date:  2015-11-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.